Loading clinical trials...

Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease | Clinical Trials | Clareo Health

UNKNOWNPHASE4

Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease

NCT01465906•Shanghai Zhongshan Hospital

View on ClinicalTrials.gov

Summary

Phrase: IV Indication: dyspnea symptom of chronic obstructive pulmonary disease (COPD) Objective: to evaluate efficacy and safety of tulobuterol patch combined with Tiotropium bromide for relieving dyspnea symptom of COPD Design: a multi-centre randomized parallel blank control study Case number: test group 80, control group 80, totally 160 Site number:7 Study period: 2010.9 - 2011.8

Eligibility

Age

40 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•people aging from 40 to 80 with self ability of judgment
•out-patients diagnosed as stable COPD according to "diagnosing and treatment guideline of COPD (2007 edition)" by Respiratory Department of Chinese Medical Association
•PFT value at screen phase meet the standard as follows: FEV1/FVC \< 70% and FEV1% among 30%-80% 15 mins after inhalation of 400ug Ventolin (i.e., moderate and severe COPD patients ).
•people who can use Tiotropium Bromide powder inhalation device
•people who join the study voluntarily and sign ICF (Informed Consent Form)

Exclusion Criteria

•people who have other acute or chronic respiratory diseases which may cause impairment of pulmonary function such as asthma
•AECOPD （acute exacerbation of COPD）
•people who got respiratory failure 1 month before the study
•people who received oral corticoid treatment 1 month before the study
•people who undergo oxygen therapy at home because of respiratory failure
•people who are allergic to β2 receptor agonist such as tulobuterol
•patients with Skin diseases such as atopic dermatitis, who are not appropriate to use transdermal patch
•patients of hyperthyroidism, hypertension, heart disease and severe arrhythmia, diabetes mellitus, who are not appropriate to useβ2 receptor agonist
•patients who have undergone pulmonary lobectomy or have tumor
•active tuberculosis patients
+10 more criteria

Locations (1)

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

November 1, 2010

Primary Completion Date

November 1, 2011

Completion Date

November 1, 2011

Last Updated

November 9, 2011

Enrollment

160

ESTIMATED participants

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

tulobuterol

DRUG

Tiotropium Bromide

DRUG

tiotropium bromide

DRUG

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGPHASE3

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769

Chronic Obstructive Pulmonary Disease

View study

RECRUITINGNA

Probiotics in Pulmonaty Rehabilitation for COPD

NCT06717659

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 9, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease

Inclusion Criteria

Exclusion Criteria

cfMSC Stem Cell Therapy Targeting COPD

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Probiotics in Pulmonaty Rehabilitation for COPD

A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease